Current Treatment Options Available for COVID-19 : A Review


Affiliations

  • Smt. B.K. Shah Medical Institute and Research Center, Sumandeep Vidyapeeth, Deemed to be University, Department of Pharmacology, Vadodara, Gujarat, 391760, India

Abstract

The World Health Organization (WHO) introduced the term 2019 novel corona virus to refer to a corona virus that affected the lower respiratory tract of patients with pneumonia in Wuhan, China. The official name of the 2019 novel corona virus is corona virus disease (COVID-19), announced by WHO. The total reported cases of COVID-19 as of 15th June, 2020 are 79,95,877 and 4,35,598 reported deaths. Non-availability of vaccines and medicines for its treatment is really threatening to the world right now. All chloroquine and Hydroxychloroquine, antibacterial therapy like azithromycin and doxycycline, antiviral therapy like lopinavir/ritonavir and remdesivir, convalescent plasma therapy, zinc, vaccines and Tocilizumab are part of possible management options and none is officially approved for the treatment. Current review of various articles by searching on PubMed is initiated with intention of creating meaningful information regarding all possible management that is available or will be available in near future of COVID-19.


Keywords

Convalescent Plasma Therapy, Corona-VIrus Disease (COVID)-19, Hydroxychloroquine, Remdesivir, Tocilizumab, Vaccine

Subject Discipline

Convalescent Plasma Therapy

Full Text:

References

Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of corona virus disease (COVID-19) during the early outbreak period: A scoping review. Infectious diseases of poverty. 2020 Dec; 9(1):12. https://doi.org/10.1186/s40249-020-00646-x. PMid: 32183901, PMCid: PMC7079521.

CDC.2019 Novel Corona virus, Wuhan, China; 2020. Accessed on 23/04/2020. https://www.cdc.gov/coronavirus/2019nCoV/summary.html.

WHO. Novel Corona virus China; 2020. Accessed on 23/04/2020/. https://www.who.int/csr/don/12-january2020-novel-coronavirus-china/en/.

https://www.worldometers.info/coronavirus/. Accessed on 15/06/2020.

Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. Therapeutic options for the treatment of 2019-novel corona virus: An evidence-based approach. Indian Journal of Pharmacology. 2020 Jan; 52(1):1. https://doi.org/10.4103/ ijp.IJP_119_20. PMid: 32201439, PMCid: PMC7074432.

Battegay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-novel Corona virus (2019nCoV): Estimating the case fatality rate-a word of caution. Swiss Medical Weekly. 2020 Feb 7; 150(0506). https://doi.org/10.4414/smw.2020.20203.

Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses-drug discovery and therapeutic options.

Nature Reviews Drug Discovery. 2016 May; 15(5):327-47. https://doi.org/10.1038/nrd.2015.37. PMid: 26868298, PMCid: PMC7097181.

Li L, Li R, Wu Z, Yang X, Zhao M, Liu J, et al. Therapeutic strategies for critically ill patients with COVID-19. Annals of Intensive Care. 2020 Dec; 10:1-9. https://doi.org/10.1186/s13613-020-00661-z. PMid: 32307593, PMCid: PMC7167303.

Dimitrov DS. The secret life of ACE2 as a receptor for the SARS virus. Cell. 2003 Dec 12; 115(6):652-53. https://doi.org/10.1016/S0092-8674(03)00976-0.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al.

Remdesivir and chloroquine effectively inhibit the recently emerged novel corona virus (2019-nCoV) in vitro. Cell research. 2020 Mar; 30(3):269-71. https://doi.org/10.1038/ s41422-020-0282-0. PMid: 32020029, PMCid: PMC7054408.

Mamidala E, Davella R, Gurrapu S. An InSilico Approach for Identification of Inhibitors as a Potential Therapeutics Targeting SARS-Cov-2 Protease. Asian Journal of Pharmaceutical Research and Health Care. 2020; 12(1):3-9.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). Clinical Infectious Diseases. 2020 Mar 9. https://doi.org/10.1093/cid/ ciaa237. PMid: 32150618, PMCid: PMC7108130.

Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of hydroxychloroquine in treatment of patients with common corona virus disease-19 (COVID-19). Journal of Zhejiang University (Medical Science). 2020 May 25; 49(2):215-19. Accessed on 23/04/2020. https://doi.org/10.3785/j.issn.10089292.2020.03.03 https://clinicaltrials.gov/ct2/show/study/NCT04261517.

Falcão MB, de Góes Cavalcanti LP, Filgueiras Filho NM, de Brito CA. Case Report: Hepatotoxicity associated with the use of Hydroxychloroquine in a Patient with COVID-19. The American Journal of Tropical Medicine and Hygiene. 2020 Jun 3; 102(6):1214-16. https://doi.org/10.4269/ajtmh.200276. PMid: 32314698, PMCid: PMC7253107.

Wang K, Chen W, Zhou YS, Lian JQ, Zhang Z, Du P, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. Bio. Rxiv. 2020 Jan 1. https://doi.org/10.1101/2020.03.14.988345

Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an openlabel non-randomized clinical trial. International Journal of Antimicrobial Agents. 2020 Mar 20; 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949. PMid: 32205204, PMCid: PMC7102549.

Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med. Mal. Infect. 2020 Mar 30; 50(384):30085-88. https://doi.org/10.1016/j.medmal.2020.03.006, https://www.sciencedirect.com/science/article/pii/S0399077X20300858. PMid: 32240719, PMCid: PMC7195369.

Conforti C, Giuffrida R, Zalaudek I, Di Meo N. Doxycycline, a widely used antibiotic in dermatology with a possible antiinflammatory action against ILâ€6 in COVIDâ€19 outbreak. Dermatologic Therapy. 2020 Jan 1. https://doi.org/10.1111/dth.13437.

Di Caprio R, Lembo S, Di Costanzo L, Balato A, Monfrecola G. Anti-inflammatory properties of low and high doxycycline doses: an in vitro study. Mediators of Inflammation. 2015 Jan 1; 2015. https://doi.org/10.1155/2015/329418. PMid: 25977597, PMCid: PMC4421036.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid19. New England Journal of Medicine. 2020 Mar 18. https:// doi.org/10.1056/NEJMo a2001282.

de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences. 2020 Mar 24; 117(12):6771-76. https://doi.org/10.1073/pnas.1922083117. PMid: 32054787, PMCid: PMC7104368.

Remdesivir in COVID-19. Accessed on 27/04/2020. https:// clinicaltrials.gov.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine. 2020 Jun 11; 382(24):2327-36. https://doi.org/10.1056/NEJMoa2007016. PMid: 32275812, PMCid: PMC7169476.

Alzoughool F, Alanagreh LA. Corona virus drugs: Using plasma from recovered patients as a treatment for COVID19. International Journal of Risk and Safety in Medicine.

Apr 13(Preprint); 1-5. https://doi.org/10.3233/JRS201017. PMid: 32310190, PMCid: PMC7306893.

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020 Apr 28; 323(16):1582-89. https://doi.org/10.1001/jama.2020.4783. PMid: 32219428, PMCid: PMC7101507.

https://icmr.nic.in/sites/default/files/upload_documents/ LOI_TPE_12042020.pdf. Accessed on 27/04/2020.

https://www.who.int/blueprint/priority-diseases/keyaction/ novel-coronavirus-landscape-ncov.pdf. Accessed on 27/04/2020.

Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? Journal of Translational Medicine. 2020 Dec; 18(1):1-5. https://doi.org/10.1186/ s12967-020-02339-3. PMid: 32290839, PMCid:PMC7154566.

Biggioggero M, Crotti C, Becciolini A, Favalli EG. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Design, Development and Therapy. 2019; 13:57. doi: 10.2147/ DDDT.S150580. https://doi.org/10.2147/DDDT.S150580. PMid:30587928, PMCid: PMC6304084.

Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 2020 May 19; 117(20):10970-75. https://doi.org/10.1073/pnas.2005615117. PMid: 32350134, PMCid: PMC7245089.

Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmunity Reviews. 2020 May; 19(7):102568. https://doi.org/10.1016/j.autrev.2020.102568. PMid: 32376398, PMCid: PMC7252115.

The use of Tocilizumab in the Management of Patients who have Severe COVID-19 with Suspected Pulmonary Hyperinflammation. Accessed on 15/06/2020. https://clinicaltrials.gov/ct2/results?cond=&term=NCT04377750.

Revised guidelines on clinical management of COVID19 as on 13th June 2020. Accessed on 15/06/2020. https://www.mohfw.gov.in/pdf/ClinicalManagementProtocolforCOVID19.pdf.


Refbacks

  • There are currently no refbacks.